[Expression of cytokines Il-6, IL-34 and M-CSFR in chronic periodontitis and its clinical significance].

PURPOSE: To detect the expression of IL-6，IL-34 and M-CSFR in chronic periodontitis and healthy gingival tissue and discuss the role of IL-6，IL-34 and M-CSFR in the etiology of chronic periodontitis. METHODS: A total of 8 patients with mild chronic periodontitis and 8 patients with severe chronic periodontitis were collected in this study. As control，8 normal gingival tissues from extracted healthy were selected. The expression of IL-6, IL-34 and M-CSFR mRNA was detected by real-time PCR; the expression of IL-6, IL-34 and M-CSFR protein was detected by Western blotting. Statistical analysis was performed using GraphPad Prism 6.0. RESULTS: The levels of IL-6, IL-34, M-CSFR mRNA and protein expression in chronic periodontitis was significantly higher than that of the normal gingival tissue(P<0.05). CONCLUSIONS: IL-6, IL-34 and M-CSFR may be closely related to the development of chronic periodontitis.

Effect of Baicalin-loaded PEGylated cationic solid lipid nanoparticles modified by OX26 antibody on regulating the levels of baicalin and amino acids during cerebral ischemia-reperfusion in rats.

Baicalin has many pharmacological activities, including neuroprotective function against ischemia and neurodegeneration. In our previous study, we found that Baicalin-loaded PEGylated cationic solid lipid nanoparticles modified by OX26 antibody (OX26-PEG-CSLN) might be a promising carrier to deliver drugs across the blood-brain barrier for the treatment of brain diseases. So, the aim of this present study was to further elucidate the mechanisms of OX26-PEG-CSLN cerebral ischemia protection by monitoring the changes of extracellular amino acids. In addition, we investigated the effect of OX26-PEG-CSLN on the excitotoxic neuronal injury as well as the pharmacokinetic profiles of baicalin in cerebrospinal fluid during ischemia-reperfusion period. The cerebrospinal fluid was collected by a microdialysis technique and divided into two parts - one part for pharmacokinetic study of baicalin using LC-MS/MS method and the other for pharmacodynamic study which was done by pre- column derivatization of the amino acids and analysis using a high-performance liquid chromatography with fluorescence detector (HPLC-FLD). The pharmacokinetic study showed that the AUC value of OX26-PEG-CSLN was 5.69-fold higher than that of the baicalin solution (Sol) (P<0.05) and the Cmax value of OX26-PEG-CSLN was 6.84-fold higher than that of the Sol (P<0.05). Moreover, the extracellular levels of glutamate (Glu), aspartic acid (Asp), glycine (Gly), taurine (Tau) and γ-aminobutyric acid (GABA) were measured for monitoring the imbalance of amino acids caused by ischemia and reperfusion. The excitotoxic index (EI) was also calculated for evaluating the imbalance between excitatory amino acid and inhibitory amino acid. The pharmacodynamic study showed that OX26-PEG-CSLN had stronger effect than Sol in reducing the content of aspartic, glutamic acid and increasing the concentrations of glycine, taurine and γ-aminobutyric acid during ischemia-reperfusion period. In conclusion, OX26-PEG-CSLN improved uptake of baicalin across the BBB into the brain, and elevated bioavailability of baicalin in cerebral spinal fluid of rats under the cerebral ischemia-reperfusion injury. OX26-PEG-CSLN had much higher protection effect against cerebral ischemia injury than Sol by relieving the excitotoxic neuronal injury via regulating amino acid levels in cerebral spinal fluid.

Drug delivery with PEGylated MoS2 nano-sheets for combined photothermal and chemotherapy of cancer.

MoS2 nanosheets functionalized with poly-ethylene glycol are for the first time used as a multifunctional drug delivery system with high drug loading capacities. Using doxorubicin as the model drug and taking advantages of the strong near-infrared absorbance of MoS2, combined photothermal and chemotherapy of cancer is realized in animal experiments, achieving excellent synergistic anti-tumor effect upon systemic administration.

PEGylated WS(2) nanosheets as a multifunctional theranostic agent for in vivo dual-modal CT/photoacoustic imaging guided photothermal therapy.

A new generation of photothermal theranostic agents is developed based on PEGylated WS2 nanosheets. Bimodal in vivo CT/photoacoustic imaging reveals strong tumor contrast after either intratumoral or intravenous injection of WS2 -PEG. In vivo photothermal treatment is then conducted in a mouse tumor model, achieving excellent therapeutic efficacy with complete ablation of tumors. This work promises further exploration of transition-metal dichalcogenides for biomedical applications, such as cancer imaging and therapy.